Ref : https://ou.edu/content/publicaffairs/archives/OUTeamDevelopsNewAntibioticFormulationtoFightMRSAandOtherAntibioticResistantBacteria.html
Wednesday, November 2, 2016
New drug that combines methicillin with polymer BPEI can combat MRSA
Ref : https://ou.edu/content/publicaffairs/archives/OUTeamDevelopsNewAntibioticFormulationtoFightMRSAandOtherAntibioticResistantBacteria.html
Friday, October 28, 2016
Natural product darwinolide may help combat fatal MRSA infection
Tuesday, January 24, 2017
New experimental antibiotic can help combat MRSA infections
"Current standard-of-care drugs for the treatment of MRSA infections are limited," said Pilch. "Furthermore, resistance to these drugs is on the rise, and their clinical effectiveness is likely to diminish in the future."
Ref : http://aac.asm.org/content/59/8/4845.full?sid=949e5603-f4b2-4eec-8e5f-f79d0c758e44
Thursday, June 4, 2015
Two common antibiotic treatments equally effective against MRSA skin infections
Researchers funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have found that two common antibiotic treatments work equally well against bacterial skin infections caused by methicillin-resistant Staphylococcus aureus (MRSA) acquired outside of hospital settings. Known as community-associated MRSA, or CA-MRSA, these skin infections have been reported in athletes, daycare-age children, students, military personnel and prison inmates, among others, and can lead to hospitalization, surgical procedures, bacteria in the blood, and in severe cases, death.
Wednesday, January 20, 2016
Novel class of antimicrobials could be effective in fighting drug-resistant MRSA infection
Thursday, January 21, 2016
Innovative compound with anti-MRSA qualities may help develop new class of antibiotics
As today’s infections develop increasing resistance to the antibiotics of the past, there is an urgent need for researchers to develop new therapeutics. Without this action, we are seriously at risk of entering a post-antibiotic world where common and traditionally minor infections could once again prove fatal. Discovering the antibacterial properties of our lead compound, the highly active quinoline thiourea, at Maynooth University is a significant first step. With further research and development, it has the potential to pave the way for a new class of antibiotic.
Thursday, December 1, 2016
Theravance Biopharma Announces FDA Approval of Expanded Label for Vibativ (telavancin)
Expanded Vibativ Label Data
- In the all-treated cSSSI patient population with baseline S. aureus bacteremia in the ATLAS I and II trials, clinical cure rates at test-of-cure were 57.1% for Vibativ-treated patients vs. 54.6% for vancomycin-treated patients.
- In the HABP/VABP patient population with at least one Gram-positive respiratory pathogen at baseline who had concurrent S. aureus bacteremia in the ATTAIN I and II trials, the 28-day all-cause mortality rate was 40.0% for Vibativ-treated patients vs. 39.5% for vancomycin-treated patients.
Thursday, October 2, 2014
Scripps Research Institute Chemists Modify Antibiotic to Vanquish Resistant Bacteria
Tuesday, April 21, 2009
White light-activated antibacterial coating-a new weapon against superbugs ?
Cutting rates of healthcare associated infections (HCAIs) such as Methicillin-resistant Staphylococcus aureus (MRSA) and Clostridium difficile (C.Diff) is a key priority for healthcare professionals. Recently in my earlier blog, I did mention that they were able to culture many bacterii from the cell phones of the health workers !.
Thogh govts., are taking many intiatives with sterlisation of the instrements, the rooms still something has to be done. But this is really something interesting which I read recently and want to share with...
Miss Zoie Aiken and her colleagues presented the work at the Society for General Microbiology meeting in Harrogate on 31 March, 2009. The veneer-like surface, made of titanium dioxide with added nitrogen. When it is activated by white light, similar to those used in hospital wards and operating theatres, it produced a decrease in the number of bacteria surviving on the test surface. Really interesting and the basis for this research is that "Titanium dioxide based coatings can kill bacteria after activation with UV light. The addition of nitrogen to these coatings enables photons available in visible light to be utilised to activate the surface and kill bacteria".
The following are the conclusions :
1. the activity of the coating is assessed against a range of different bacteria such as MRSA and other organisms which are known to cause infections in hospitals. At present researchers claim that the coating is active against Escherichia coli. However, E. coli is more difficult to kill than bacteria from the Staphylococcus group which includes MRSA and the results to date are encouraging.
2. the coating has currently been applied onto glass using a method called APCVD (atmospheric pressure chemical vapour deposition and the researchers want to try out plastic.
Once again congrats and best wishes for further research..
Source : http://www.sgm.ac.uk/
Thursday, November 6, 2014
Scientists develop new drug as alternative to antibiotics
In a small patient trial, the drug was shown to be effective at eradicating the superbug Methicillin-resistant Staphylococcus aureus (MRSA).
Monday, April 12, 2010
2-aminoimidazole/triazole conjugate re-sensitizes multi-drug resistant strains of bacteria to the effects of conventional antibiotics...
Monday, November 23, 2015
Tamoxifen drug clears MRSA, reduces mortality
In continuation of my update on Tamoxifen
Thursday, April 8, 2021
FDA Approves Kimyrsa (oritavancin) for the Treatment of Adult Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Melinta Therapeutics, LLC (Melinta), a commercial-stage company focused on the development and commercialization of novel antibiotics, today announced that the U.S. Food and Drug Administration (FDA) has approved Kimyrsa (oritavancin) for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of designated Gram-positive microorganisms, including methicillin-resistant Staphylococcus aureus (MRSA). Kimyrsa is a lipoglycopeptide antibiotic that delivers a complete course of therapy for ABSSSI in a single, one hour 1,200 mg infusion.
“The approval of Kimyrsa demonstrates Melinta’s commitment to provide innovative therapies to patients with acute and life-threatening illnesses,” said Christine Ann Miller, President and Chief Executive Officer of Melinta. “We have responded to the requests of the medical community to provide an oritavancin product with a shorter infusion time. We believe that with the approval of Kimyrsa and product availability this summer, physicians and patients will now have a compelling new one-dose alternative to the current standard of multi-dose regimens for ABSSSI.”
ABSSSI affect approximately 14 million patients in the U.S. each year, are responsible for over 3 million visits to the Emergency Room annually and represent the 8th most common cause of Emergency Department hospital admissions1,2. ABSSSI cost U.S. hospitals $4 billion each year, with a 4.1-day average length of stay for hospitalized ABSSSI patients.2
“Kimyrsa is an important new treatment option that will provide clinicians with additional flexibility to treat ABSSSI patients in multiple care settings, without the need for hospitalization,” said Andrew Dold, D.O., member of a private infectious disease practice covering the Greater Atlanta Region. “Single-dose, long-acting antibiotics, such as Kimyrsa, may be especially beneficial for patients who lack the support or resources to adhere to multiple intravenous administrations.”
The efficacy and safety of Kimyrsa were established in the SOLO clinical trials with another oritavancin product, Orbactiv. The SOLO trials were randomized, double-blind, multicenter studies that evaluated a single 1,200 mg IV dose of oritavancin against twice-daily vancomycin for the treatment of ABSSSI in 1,987 adult patients and assessed one of the largest subsets of documented MRSA infection (405 patients). These trials demonstrated that 1,200 mg one-dose IV oritavancin infusion was as effective as 7-to-10 days of twice-daily vancomycin (1 g or 15 mg/kg) for the primary and secondary endpoints. Kimyrsa approval is based on the results of an open-label, multi-center, pharmacokinetics study, which compared Kimyrsa administered over 1 hour (N=50) to Orbactiv administered over 3 hours (N=52) for the treatment of adult patients with ABSSSI.
Michael Waters, M.D. and lead investigator in the PK clinical trial stated, “Kimyrsa was shown to be comparable to Orbactiv with a favorable safety profile. I’m pleased that these outcomes support the approval of Kimyrsa to provide oritavancin with a shorter infusion time and lower infusion volume. With these features, Kimyrsa can further enhance the treatment experience for the patient and efficiency of administration in clinical practice.”
Wednesday, May 25, 2011
Linezolid more effective than vancomycin in treating ventilated patients with MRSA pneumonia: Study
Linezolid more effective than vancomycin in treating ventilated patients with MRSA pneumonia: Study
Monday, May 24, 2010
Thursday, February 21, 2013
New Antibiotic May Treat Skin Infections in Shorter Time - Drugs.com MedNews
Monday, May 31, 2010
Plectasin - a new weapon against highly resistant microbes ?..
In this process, plectasin behaves like a thief which steals the stones off a mason. 'It binds to a cell-wall building block called lipid II and thus prevents it from being incorporated ,' Professor Sahl explains. 'However, bacteria cannot live without a cell wall.' It comes as no surprise that the most famous antibiotic penicillin also inhibits cell-wall synthesis...
Wednesday, June 11, 2014
Promising discovery in fight against antibiotic-resistant bacteria .....
Monday, April 25, 2016
Allergan Announces FDA Approval of Updated Label for New Dosing Regimen for Dalvance (dalbavancin)
Thursday, December 10, 2009
MSRA can be stopped before it becomes dangerous ....
C. Jeffrey Brinker research group has determined that the very first stage of staph infection, when bacteria switch from a harmless to a virulent form, occurs in a single cell and that this individual process can be stopped by the application of a simple protein (as against the belief that, staph infections are caused by many bacterial cells that signal each other to emit toxins. The signaling process is called quorum sensing). The most significant results from the researchers are :
1. isolation of Staphylococcus aureus bacteria in individual (isolation of an individual bacterium
previously had been achieved only computationally);
2. demonstration of release of signaling peptides from a single cell, not a quorum &
3. introduction of an inexpensive, very low-density lipoprotein (VLDL) to bind to the
messenger peptide, they stopped the single cell from reprogramming itself.
One aspect of experimental rigor was the team's ability to organize living cells into a nanostructured matrix. The researchers has already done it with yeast, and just extended the process to bacteria. Researchers are optimistic about finding a mechanism to locate bacteria reprogramming in the body so that the antidote can be delivered in time. If they achieve what they are optimistic, so there will selectivity of targeting the bacteria (human gastro-intestinal system contains many useful bacteria) which in my opinion will be a remarkable feat....
Ref : http://www.nature.com/nchembio/journal/vaop/ncurrent/full/nchembio.264.html